Navigation Links
New drug improves survival in multiple myeloma relapse, Moffitt Cancer Center researchers say
Date:1/23/2013

Researchers at Moffitt Cancer Center and colleagues have investigated the safety, efficacy and the maximum tolerated dose of pomalidomide for patients with multiple myeloma who have disease relapsed after treatments with other drugs, such as bortezomib and lenalidomide. This phase I clinical trial enrolled 38 patients, and pomalidomide provided a minimal or better response for 42 percent of the patients, a partial response or better for 21 percent, and a complete response for 3 percent.

The study, a collaborative effort among researchers from Moffitt, Dana-Farber Cancer Institute, Hackensack University Medical Center, Multiple Myeloma Research Consortium, and Celgene Corporation, appeared in the Dec. 14 issue of Blood, the journal of the American Society of Hematology.

According to the authors, almost all multiple myeloma patients treated with bortezomib, lenalidomide or thalidomide relapse, and survival times shorten progressively with each subsequent relapse. Effective new treatments that re-establish tumor response are urgently required to improve outcomes for these patients.

"This open-label, phase I, dose-escalation study was primarily conducted to evaluate the maximum tolerated dose of pomalidomide," said study co-author Daniel Sullivan, M.D., associate center director for clinical investigations at Moffitt. "The secondary objective was to assess safety of pomalidomide when given with or without dexamethasone."

The researchers found that pomalidomide, given in escalating doses (from 2 to 5 mg per day for 21 of 28 days) in combination with low doses of dexamethasone, demonstrated "encouraging activity with manageable toxicity." The researchers noted that there was a low incidence of peripheral neuropathy in their study patients, all of whom had eventually failed past treatment with drugs known to be associated with neurotoxicity. Common adverse events included neutropenia, anemia, thrombocytopenia and fatigue. These adverse events were generally manageable and are not unexpected in this clinical situation.

Ongoing phase II studies have confirmed the safety and efficacy of this drug in patients with relapsed myeloma. The Food and Drug Administration is considering the drug for approval for this patient population.


'/>"/>

Contact: Kim Polacek
kim.polacek@moffitt.org
813-745-7408
H. Lee Moffitt Cancer Center & Research Institute
Source:Eurekalert

Related medicine news :

1. Novel gene-searching software improves accuracy in disease studies
2. Gene expression improves the definition of a breast cancer subtype
3. Combination of imaging exams improves Alzheimers diagnosis
4. Palliative care improves outcomes for seniors
5. Metformin improves blood glucose levels and BMI in very obese children
6. New Treatment Aids Weight Loss, Improves Diabetes in Monkeys
7. Networks it takes a village approach improves dementia care and informs research, study shows
8. 1 week at a health spa improves your health, study shows
9. First-of-its-kind program improves outcomes for seniors admitted for trauma
10. California improves its ranking on March of Dimes Annual Preterm Birth Report Card
11. Smart drug improves survival in older patients with acute myeloid leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... April 26, 2017 , ... Infertility may ... pelvic conditions and has helped many women become pregnant upon treating their diagnosis. ... office-based and simple outpatient evaluations. We can provide the necessary information to ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... launched a unique website ( CRISPRCas.pioneer.com ) that demonstrates how this advanced plant ... produce more and better food, with fewer resources. It highlights the business’ principles, ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... proud to announce that it has received 510(k) clearance from the U.S. Food ... and the MyoCycle Pro. , Both devices are stationary cycling systems that use ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... have signed an agreement to be the preferred physical therapy provider for Derby ... returning them to Derby City CrossFit as quickly and effectively as possible, ProRehab’s ...
(Date:4/25/2017)... ... April 25, 2017 , ... As President Trump challenges the ... how his administration could impact the employee benefits industry. James Slotnick, AVP, Government ... likely to make it through Congress. His discussion will focus on the current ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)...  CVS Pharmacy, the retail division of CVS ... design to enhance the retail customer experience with ... and expanded beauty selections paired with informational signage ... offerings. Together with its innovative digital programs, these ... experience at CVS Pharmacy.  "Pharmacy ...
(Date:4/20/2017)... 20, 2017 Eyevensys, a private ... non-viral gene expression technology that enables the safe, local, ... address a wide range of ophthalmic diseases, announces it ... products Regulatory Agency (MHRA) to advance its technology into ... ...
(Date:4/19/2017)... , April 19, 2017 Cardiology devices segment is ... period The Cardiology Devices segment is likely to ... 15 Mn in 2018 over 2017. By the end of ... valuation close to US$ 700 Mn, expanding at a CAGR ... dominated the Asia Pacific reprocessed medical ...
Breaking Medicine Technology: